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Abstract 
Uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists with 
fast off-rate (UFO) may represent promising drug candidates for various 
neurodegenerative disorders. In this study, we report that bis(propyl)-
cognitin, a novel dimeric acetylcholinesterase inhibitor and γ-aminobutyric 
acid subtype A receptor antagonist, is such an antagonist of NMDA receptors. 
In cultured rat hippocampal neurons, we demonstrated that bis(propyl)-
cognitin voltage-dependently, selectively, and moderately inhibited NMDA-
activated currents. The inhibitory effects of bis(propyl)-cognitin increased with 
the rise in NMDA and glycine concentrations. Kinetics analysis showed that 
the inhibition was of fast onset and offset with an off-rate time constant of 
1.9 s. Molecular docking simulations showed moderate hydrophobic 
interaction between bis(propyl)-cognitin and the MK-801 binding region in the 
ion channel pore of the NMDA receptor. Bis(propyl)-cognitin was further found 
to compete with [3H]MK-801 with a Ki value of 0.27 μm, and the mutation of 
NR1(N616R) significantly reduced its inhibitory potency. Under glutamate-
mediated pathological conditions, bis(propyl)-cognitin, in contrast to 
bis(heptyl)-cognitin, prevented excitotoxicity with increasing effectiveness 
against escalating levels of glutamate and much more effectively protected 
against middle cerebral artery occlusion-induced brain damage than did 
memantine. More interestingly, under NMDA receptor-mediated physiological 
conditions, bis(propyl)-cognitin enhanced long-term potentiation in 
hippocampal slices, whereas MK-801 reduced and memantine did not alter 
this process. These results suggest that bis(propyl)-cognitin is a UFO 
antagonist of NMDA receptors with moderate affinity, which may provide a 
pathologically activated therapy for various neurodegenerative disorders 
associated with NMDA receptor dysregulation. 
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Introduction 
Neurodegenerative disorders are among the leading cause of 
death in the elderly, and this medical problem is expected to become 
more serious as the population continues to age. N-Methyl-D-aspartate 
(NMDA)3 receptor overactivation-induced excitotoxicity is clearly 
implicated in a variety of acute and chronic neurodegenerative 
disorders (1,–4). Thus, the NMDA receptor has been considered an 
attractive therapeutic target for the development of neuroprotectants. 
However, the NMDA receptor, as the major excitatory 
neurotransmitter receptor in the central nervous system, mediates 
many important physiological processes, such as excitatory 
neurotransmission, synaptic plasticity, learning and memory, and cell 
survival (5,–8). The therapeutic potential of many NMDA receptor 
antagonists, therefore, was limited, and they failed in clinical trials 
because of their psychotropic side effects and memory-impairing 
effects resulting from the blockade of NMDA receptor-mediated 
physiological activities (9, 10). Clinically well tolerated and effective 
NMDA receptor antagonists for the therapy of neurodegenerative 
disorders have been pursued over the past several decades. 
The strategies applied to develop effective and well tolerated 
neuroprotective drugs are based on the principle that drugs should 
interact with their targets only during states of pathological and not 
physiological activation. Such drugs have been coined pathologically 
activated therapeutic (PAT) drugs by Lipton (11). For the treatment of 
neurodegenerative disorders accompanied by NMDA receptor-mediated 
excitotoxicity, uncompetitive NMDA receptor antagonists with fast off-
rate (UFO), but not competitive and noncompetitive ones, fit in with 
the PAT strategy. An uncompetitive antagonist is defined as a drug 
whose inhibitory effect is contingent upon prior activation of the 
channel by agonist, and a fixed concentration of antagonist blocks the 
response to high concentrations of agonist to a greater extent than the 
response to low concentrations of agonist (11). A clear advantage of 
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compounds of this type is that they preferentially blocked 
overactivated (in a tonic rather than phasic manner) channels while 
sparing physiological neurotransmission mediated by NMDA receptors 
(12,–14). However, for uncompetitive antagonists, the off-rate and 
affinity further determine the clinical tolerability. Taking dizocilpine 
(MK-801) as an example, because it binds very tightly with and 
dissociates very slowly from the receptor, it blocks excessive as well as 
normal activation, resulting in deleterious side effects. Thus, 
uncompetitive NMDA receptor antagonists with moderate to low 
receptor affinity and with fast on/off-rate kinetics have been the center 
of interest in the search for neuroprotective drugs with beneficial 
therapeutic potentials for the treatment of various acute and chronic 
neurodegenerative disorders (10, 15,–17). 
Over the past decade, our group has developed a series of 
dimeric acetylcholinesterase (AChE) inhibitors derived from tacrine 
linked with different numbers of methylene (-CH2-) groups (18). These 
dimers have been demonstrated to inhibit AChE and γ-aminobutyric 
acid subtype A (GABAA) receptors in a tether-dependent manner (19, 
20). The reduction of acetylcholine breakdown by AChE inhibitors may 
increase acetylcholine levels in the brain and contribute to learning 
and memory. Furthermore, blockade of GABAA receptors can increase 
the release of acetylcholine (21) and facilitates long term potentiation 
(LTP) induction (22), whereas activation of GABAA receptors may 
deteriorate aging-associated memory decline (23). In our previous 
study, bis(heptyl)-cognitin (also known as bis(7)-tacrine), heptylene-
linked tacrine dimer, has been found to prevent glutamate-induced 
excitotoxicity by blocking NMDA receptors. However, the effectiveness 
of bis(heptyl)-cognitin neuroprotection decreases with the increase of 
glutamate concentration (24). Therefore, besides their AChE and 
GABAA receptor inhibitions in a tether-dependent manner, at the 
beginning of this study, we speculated that this series of 
multifunctional dimers might possess tether-dependent effects on 
NMDA receptors and different manners of neuroprotection. By 
comparison of their actions on NMDA receptors, bis(propyl)-cognitin 
emerges as a promising neuroprotective drug candidate among these 
novel dimers. We demonstrate that this dimer is an uncompetitive 
NMDA receptor antagonist with moderate affinity, fast off-rate, 
effective neuroprotective activities against glutamate-induced neuronal 
cell death without obvious cytotoxicity in vitro and middle cerebral 
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artery occlusion (MCAO)-induced brain damage in vivo, and 
enhancement of LTP. These findings strongly suggest that this dimer 
may be developed to a PAT drug possessing considerable therapeutic 
potential for various associated neurodegenerative disorders. 
Experimental Procedures 
Primary Neuron Cultures  
Primary cultured hippocampal neurons were obtained from 18-
day-old Sprague-Dawley rat embryos as previously described with 
modifications (25). Briefly, The hippocampi were dissected and 
incubated with 0.25% trypsin at 37°C for 12 min. Cells were then 
mechanically dissociated by using a Pasteur pipette with a fire-
narrowed tip in culture medium and plated at a density of 2 × 105 
cells/ml on 35-mm culture dishes precoated with poly-l-lysine (10 
μg/ml). Cells were maintained in neurobasal/B27 medium containing 
0.5 m glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin 
under a humidified atmosphere of 5% CO2, 95% air at 37°C. Half-
changes of medium were done twice weekly. Cells were used for 
electrophysiological recording 7–15 days after plating. 
Cerebellar granule neurons (CGNs) were prepared from 8-day-
old Sprague-Dawley rats (the animal care facility, Hong Kong 
University of Science and Technology) as described previously (24). 
Briefly, neurons were seeded on 96-well plates precoated with poly-l-
lysine (10 μg/ml) at a density of 2 × 106 cells/ml in basal modified 
Eagle's medium containing 10% fetal bovine serum, 25 m KCl, 2 m 
glutamine, and penicillin (100 units/ml)/streptomycin (100 μg/ml). 
Cytosine arabinoside (10 μm) was added to the culture medium 24 h 
after plating to limit the growth of non-neuronal cells. With the use of 
this protocol, 95–99% of the cultured cells were granule neurons. All 
experiments were performed in CGNs at 7 or 8 days in vitro. 
HEK293T Cell Culture and Transfection  
HEK293T cells (ATCC, Manassas, VA) were grown as a 
monolayer using passage numbers less than 25 and maintained in 
Dulbecco's modified Eagle's medium (Invitrogen), supplemented with 
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10% fetal bovine serum (Invitrogen) and 2 m L-glutamine in a 
humidified incubator at 37°C with 5% CO2. At 1 day prior to 
transfection, exponentially growing cells were plated at a density of 1 
× 105 cells/ml on 35-mm culture dishes precoated with poly-L-lysine 
(10 μg/ml). The cells were transiently transfected using 
Lipofectamine/PLUS reagents (Invitrogen) with a ratio of cDNA for rat 
NMDA receptor subunits for NR1-1a/NR2A (gift of Dr. Anne 
Stephenson from the Department of Pharmaceutical and Biological 
Chemistry, School of Pharmacy, University of London) of 1:3. An NR1-
1a (N616R) mutation was introduced by site-directed mutagenesis 
using the QuikChange kit (Stratagene, La Jolla, CA) according to the 
manufacturer's directions and confirmed by DNA sequencing. Following 
transfection, the cells were maintained for 24 h in a glutamine-free 
medium containing 100 μm D(-)-2-amino-5-phosphonopentanoic acid 
and 200 μm ketamine to prevent NMDA receptor-mediated 
excitotoxicity. 
Whole-cell Electrophysiological Recordings  
Whole-cell patch clamp recordings were carried out at room 
temperature (22–24°C) on the stage of an inverted phase-contrast 
microscope using an Axopatch 200B patch amplifier (Axon 
Instruments, Burlingame, CA). Before each experiment, the culture 
medium was removed, and the cells were rinsed completely and 
continuously superfused with a solution containing 150 m NaCl, 5 
m KCl, 0.25 m CaCl2, 10 m glucose, 0.001 m glycine, 0.001 m 
tetrodotoxin, 0.01 m (−)-bicuculline methiodide, and 10 m HEPES 
(the pH was adjusted to 7.4 with NaOH, and the osmolarity was 
adjusted to ∼340 mos with sucrose). The low concentration of Ca2+ 
was used to minimize the calcium-dependent desensitization of NMDA-
activated currents. Pipettes pulled from borosilicate glass (TW-150F, 
World Precision Instruments, Sarasota, FL) had resistances of 2–4 
megaohms when filled with pipette solution containing 140 m CsCl, 
10 m EGTA, 10 m HEPES, and 5 m MgATP with pH 7.3 and 315 
mos in osmolarity. A small patch of membrane underneath the tip of 
the pipette was aspirated to form a gigaseal, and then a more negative 
pressure was applied to rupture it, thus establishing a whole-cell 
configuration. The adjustment of capacitance compensation and series 
resistance compensation was done before recording the membrane 
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currents. The holding potential was set at −50 mV except when 
otherwise indicated. Data were acquired using pClamp 9.0 software 
(Axon Instruments). Currents were filtered at 2 kHz and digitized at 5 
kHz. 
Drug Application  
Drugs used in the experiments included NMDA, AMPA, kainate, 
tacrine, memantine, MK-801, tetrodotoxin, and (−)-bicuculline 
methiodide. All of these drugs were purchased from Sigma. Bis(n)-
cognitins were prepared according to the method described previously 
(19). Each drug was dissolved daily in the Mg2+-free external solution 
just before use and applied with a fast step perfusion system (SF-77B; 
Warner Instruments, Hamden, CT) through 3-barrel square glass 
tubing. The distance from the tube mouth to the cell examined was 
about 100 μm. The application of each drug could be driven by gravity 
and controlled by the corresponding valve. The solution exchange rate 
was estimated according to Chen et al. (26) with a time constant of 
2.38 ± 0.82 ms (n = 21, mean ± S.E.). Cells or patches were 
constantly bathed in the normal external solution flowing from one 
tube connected to a larger reservoir between drug applications (0.5–
0.8 ml/min). 
Molecular Docking Analysis  
The homology model of the ion channel of NMDA receptors was 
constructed based on the x-ray crystal structure of the potassium 
channel KcsA (Protein Data Bank code 1BL8), and performed using 
ICM sequence-structure alignment and the BuildModel algorithm. ICM 
sequence-structure alignment is based on the primary sequences of 
subunits of NR1, NR2B, and the primary sequence of potassium 
channel KcsA (Escherichia coli). The homology model was optimized by 
Monte Carlo minimization. Three independent runs of the refinement 
procedure were performed, each run including 100,000 Monte Carlo 
minimization steps. The ICM Protein Health tool was used to check the 
quality of the refinement. Molecular docking was performed using the 
ICM-Pro 3.4-8a program (Molsoft). According to the ICM method, the 
molecular system was described using internal coordinates as 
variables. Energy calculations were based on the ECEPP/3 force field 
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with a distance-dependent dielectric constant. The biased probability 
Monte Carlo minimization procedure was used for global energy 
optimization. The binding between the compounds and the NMDA 
receptor was evaluated with a full-atom ICM ligand binding score 
calculated as follows, Sbind = Eint + TΔSTor + Evw + 1Eel + 2Ehb + 3Ehp 
+ 4Esf, where Evw, Eel, Ehb, Ehp, and Esf are van der Waals, 
electrostatic, hydrogen bonding, and nonpolar and polar atom 
solvation energy differences between bound and unbound states, 
respectively. Eint is the ligand internal strain, ΔSTor is its conformational 
entropy loss upon binding, T = 300 K, and αi are ligand- and receptor-
independent constants. A more negative binding score represents a 
more favorable binding interaction. 
Receptor-ligand Binding Assay  
The binding assay was performed as described (24) with 
modifications. Synaptic plasma membrane was prepared from the 
cerebella of 15-day-old Sprague-Dawley rats by using discontinuous 
sucrose density gradients. The receptor ligand binding was performed 
in triplicate using 150–200 μg of synaptic plasma membrane protein 
and 4 n [3H]MK-801 (American Radiolabeled Chemicals Inc., St. 
Louis, MO) incubated with different concentrations of testing 
compounds; nonspecific binding was determined by an excess of the 
unlabeled MK-801. After collecting the samples on Whatman GF/B 
filters by rapid filtration with an MD-24 sample harvester, filtrated 
tissue on filters was soaked into scintillation mixtures overnight and 
measured in a scintillation counter (Wallac 1209, Rackbeta (Turku, 
Finland)). Specific 3H-ligand binding to receptors was determined by 
subtracting the nonspecific count from the total, which is defined by 
0.1 m unlabeled MK-801. 
Measurement of Neurotoxicity  
The percentage of surviving neurons in the presence of 
bis(propyl)-cognitin and/or glutamate was estimated by determining 
the activity of mitochondrial dehydrogenases with a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(24). The assay was performed according to the specifications of the 
manufacturer (MTT kit I, Roche Applied Science). Briefly, the neurons 
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were cultured in 96-well plates, 10 μl of 5 mg/ml MTT labeling reagent 
was added to each well containing cells in 100 μl of medium, and the 
plate was incubated for 4 h in a humidified incubator at 37°C. After the 
incubation, 100 μl of the solvating solution (0.01  HCl in 10% SDS 
solution) was added to each well for 17–18 h. The absorbance of the 
samples was measured at a wavelength of 570 nm with 630 nm as a 
reference wavelength. Unless otherwise indicated, the extent of MTT 
conversion in cells exposed to glutamate is expressed as a percentage 
of the control. 
Transient Focal Cerebral Ischemia  
The MCAO model was made on Male Sprague-Dawley rats (280–320 g) 
after anesthesia by injection of chloral hydrate (350 mg/kg 
intraperitoneally) as described previously with minor modifications 
(27). Briefly, a nylon filament with a rounded tip was advanced from 
the external carotid artery into the lumen of the internal carotid artery 
until laser Doppler flowmetry (PF5000, Perimed (Stockholm, Sweden)) 
showed a sharp decrease of the regional blood flow of middle cerebral 
artery to ∼20% of the base-line value. Two hours after onset of 
ischemia, reperfusion was allowed by withdrawal of the suture thread. 
The animals from the sham group received the same operation 
procedure except without the insertion of the nylon filament. 24 h 
after the reperfusion, neurological deficits were evaluated by a 3-point 
grading scale (28). Immediately after scoring of neurological deficits, 
rats were killed with an overdose of 10% chloral hydrate. Brains were 
sectioned into seven 2-mm coronal slices by use of a rat brain matrix 
(RBM 4000C; ASI Inc., Warren, MI) and stained with 2% 2,3,5-
triphenyltetrazolium chloride. The infarct volume % = (contralateral 
volume − ipsilateral non-ischemic volume)/contralateral volume × 
100%, and the edema extent = (ipsilateral volume − contralateral 
volume)/contralateral volume × 100%. 
Preparation of Slices  
All experiments were carried out on transverse slices of the 
Wistar rat hippocampus (males, age 3–4 weeks, weight 40–80 g). The 
brains were rapidly removed after decapitation and placed in cold 
oxygenated (95% O2, 5% CO2) media. Slices were cut at a thickness 
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of 350 μm using a Campden Vibroslice and placed in a storage 
container containing oxygenated media at room temperature (20–
22°C) for 1 h. The slices were then transferred to a recording chamber 
for submerged slices and continuously superfused at a rate of 5–6 
ml/min at 30–32°C. The control media contained 120 m NaCl, 2.5 
m KCl, 1.25 m NaH2PO4, 26 m NaHCO3, 2.0 m MgSO4, 2.0 m 
CaCl2, 10 m D-glucose. All solutions contained 100 μm picrotoxin 
(Sigma) to block GABAA receptor-mediated response. 
LTP Recording  
The slices were transferred to the recording chamber, in which it was 
held submerged between two nylon nets and maintained at 30–32°C. 
The chamber consisted of a circular well of a low volume (1–2 ml) and 
was perfused constantly at a rate of 4–5 ml/min. Standard 
electrophysiological techniques were used to record field potentials. All 
experiments were carried out in the dentate gyrus, with presynaptic 
stimulation applied to the medial perforant pathway of the dentate 
gyrus using a bipolar insulated tungsten wire electrode, and field 
excitatory postsynaptic potentials (EPSPs) recorded at a control test 
frequency of 0.033 Hz from the middle one-third of the molecular layer 
of the dentate gyrus with a glass microelectrode. In each experiment, 
an input-output curve (afferent stimulus intensity versus EPSP 
amplitude) was plotted at the test frequency. For all experiments, the 
amplitude of the test EPSP was adjusted to one-third of maximum (1–
1.2 mV), and base-line synaptic transmission was monitored for 30 
min before drug administration or delivering either high or low 
frequency stimulation. LTP was evoked by high frequency stimulation 
(HFS) consisting of eight trains, each of eight stimuli at 200 Hz, 
intertrain interval of 2 s, with the stimulation voltage increased during 
the HFS so as to elicit an initial EPSP of the train of double the normal 
test EPSP amplitude. Agents tested in this study were perfused over 
the slices for 60 min prior to HFS. Control (vehicle alone) and 
experimental levels of LTP were measured on slices prepared from the 
same hippocampus. Electrical signals were collected with an Axoclamp-
700B and were analyzed using pClamp 10.2 (Axon Instruments). All 
values were normalized to this base line, and all values of LTP reported 
here were calculated as the changes in field EPSP amplitude measured 
60 min after tetanic stimulation. 
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Data Analysis  
All data are the means ± S.E. for n independent observations, and 
statistical analyses were performed using Student's t test. 
Concentration-response curves were analyzed using a four-parameter 
logistic equation of the form, Y = Ymin + (Ymax − Ymin)/(1 + 
10∧((logEC50 − X)*Hill slope)), where Y is the response at a given 
concentration, Ymax and Ymin are the maximum and minimum response, 
X is the logarithmic value of the concentration, and Hill slope is the 
slope factor of the curve. EC50 (IC50 for inhibition) is the concentration 
that gives a response halfway between Ymax and Ymin. 
Results 
Inhibition of NMDA-activated Currents by Bis(n)-
cognitins  
To look into tether-dependent effects of the series of tacrine dimers 
(i.e. bis(n)-cognitins) on NMDA receptors, we examined IC50 values of 
bis(n)-cognitins to inhibit NMDA-activated currents and voltage 
dependence of inhibition by using patch clamp techniques. In primary 
cultured rat hippocampal neurons, 30 μm NMDA-activated currents 
exhibited slight or no desensitization. As shown in Fig. 1A, bis(n)-
cognitins, when co-applied with NMDA, inhibited NMDA-activated 
currents (INMDA) at a holding potential of −50 mV in a concentration-
dependent manner. The IC50 value and slope factor for bis(propyl)-
cognitin were 0.52 ± 0.05 μm and 0.74 ± 0.04, respectively. By 
comparison of the inhibitory effects of bis(n)-cognitins at holding 
potentials from −70 to +50 mV, bis(propyl)-cognitin showed the 
strongest voltage-dependent decrease of inhibition to INMDA (Fig. 1B). 
The reversal potential value was not changed by bis(propyl)-cognitin. 
Over the concentrations examined, none of bis(n)-cognitins applied 
alone activated detectable currents. 
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Bis(propyl)-cognitin Selectively Inhibits INMDA in an 
Agonist-dependent Manner  
We further examined the selectivity of bis(propyl)-cognitin 
inhibition among ionotropic glutamate receptors. As shown in Fig. 2A, 
bis(propyl)-cognitin had no detectable effect on steady-state currents 
activated by 30 μm AMPA or kainic acid even at a concentration of 10 
μm, although it inhibited INMDA by about 65% at 1 μm. We then tested 
whether preapplication of bis(propyl)-cognitin had any effect on the 
subsequent NMDA-activated currents. It was evident from Fig. 2B that 
preapplied bis(propyl)-cognitin had no detectable effect on NMDA-
activated currents, and bis(propyl)-cognitin could only exert an 
inhibitory effect when NMDA receptors were activated by co- or 
preapplication of NMDA, suggesting an agonist-dependent mechanism 
of bis(propyl)-cognitin inhibition. Fig. 2C further demonstrated that 
current amplitude of NMDA co-applied with bis(propyl)-cognitin 
decreased gradually and reached a steady-state level within several 
applications of NMDA in the presence of bis(propyl)-cognitin, and the 
NMDA-activated current amplitude gradually recovered from the 
blockade upon the repeated application of NMDA in the absence of 
bis(propyl)-cognitin. 
Bis(propyl)-cognitin Inhibits INMDA in an Uncompetitive 
Manner  
To distinguish possible patterns (competitive, noncompetitive, 
or uncompetitive mechanism) of interaction between bis(propyl)-
cognitin and NMDA receptors, we examined the effect of a fixed 
concentration of bis(propyl)-cognitin (0.3 μm) on currents activated by 
NMDA at concentrations from 1 to 1000 μm. As shown in Fig. 3A, the 
concentration-response curve for NMDA-activated currents was shifted 
downward, with the maximum response reduced by about 50%. The 
EC50 value (29.89 ± 3.37 μm versus a control value of 42.24 ± 3.84 
μm; p < 0.05) and the slope factor of the NMDA concentration-
response curve (0.99 ± 0.02 versus a control value of 1.11 ± 0.03; p 
< 0.05) were decreased in the presence of bis(propyl)-cognitin. A 
further plot of percentage inhibition against NMDA concentrations 
revealed that the inhibitory effect increased with the increase of NMDA 
concentration (Fig. 3A, inset). Furthermore, the concentration-
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response curve for bis(propyl)-cognitin inhibition was shifted leftward, 
with the IC50 value reduced from 0.52 μm (nH = 0.74) to 0.21 μm (nH 
= 0.76) (p < 0.05). 
Similarly, we investigated the effect of glycine on the 
bis(propyl)-cognitin inhibition of INMDA by changing the glycine 
concentrations from 0.1 to 10 μm in the external solution. As reported 
by others, the decrease of glycine concentrations resulted in a 
decrement of INMDA amplitude (data not shown). It could be seen from 
Fig. 3B that the inhibitory effect of bis(propyl)-cognitin on INMDA 
increased with the increase of glycine concentration in the external 
solution. The concentration-response curve for bis(propyl)-cognitin 
inhibition in the presence of 10 μm glycine was shifted leftward, with 
the IC50 value decreased to 0.28 ± 0.02 μm from 1.23 ± 0.08 μm in 
the presence of 0.1 μm glycine and with the slope factor basically 
unchanged (0.79 for 10 μm glycine versus 0.74 for 0.1 μm glycine, p 
> 0.05). 
Bis(propyl)-cognitin Inhibition of INMDA Is of Fast Onset 
and Offset Kinetics  
The kinetics of onset and offset (τon and τoff) of the inhibition 
were further investigated by fitting the changes of current amplitudes 
upon the application and removal of bis(propyl)-cognitin with single 
exponential functions. An example of single exponential fits to the 
onset and offset of inhibition is shown in Fig. 4A. The inverse of the 
onset and offset time constants derived from such fits was plotted as a 
function of bis(propyl)-cognitin concentrations and fitted with linear 
functions in Fig. 4B. The inverse of τon was significantly correlated with 
bis(propyl)-cognitin concentrations (p < 0.001), indicating that 
bis(propyl)-cognitin inhibition proceeded more quickly at higher 
concentrations. The inverse of τoff was not correlated with bis(propyl)-
cognitin concentrations (p > 0.05). The mean value of τoff was 1911.5 
± 207.2 ms. Based on the on- and off-rate time constants, a Kd value 
of 0.68 μm was calculated for bis(propyl)-cognitin by the equation, Kd 
= koff/kon (kon = (1/τon − 1/τoff)/[B3C]; koff = 1/τoff), which was close to 
the value (0.52 μm) obtained from the concentration-response 
relationship. 
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Acting Site(s) Mapping for Bis(propyl)-cognitin on the 
NMDA Receptor  
To gain insight into the acting site(s) of bis(propyl)-cognitin on 
the NMDA receptor, molecular docking simulation was performed. 
Bis(propyl)-cognitin showed favorable interaction with the active site 
of the ion channel of NMDA receptors, with a binding score of −29.76. 
As a reference, a binding score of −33 was obtained for the known 
NMDA receptor uncompetitive antagonist memantine. The NH group of 
bis(propyl)-cognitin formed an additional hydrogen bond with the CO 
group of Val640 of the NR2B (2.79 Å). The cyclohexane in the 
bis(propyl)-cognitin molecule was located in the depth of the 
hydrophobic pocket formed by Asn616 of the NR1 subunit and by Phe614 
and Asn615 of the NR2B subunit (Fig. 5A). Furthermore, as illustrated in 
Fig. 5B, bis(propyl)-cognitin apparently inhibited [3H]MK-801 binding 
to NMDA receptors, with an IC50 value of 0.36 ± 0.07 μm (Ki = 0.27 ± 
0.05 μm). It has been reported that the Asn616 residue in the pore 
region is closely involved in the acting pocket of many open channel 
blockers (29). We next examined the effect of NR1(N616R) mutation 
on bis(propyl)-cognitin inhibition. As indicated in Fig. 5C, single 
residue mutation in NR1 significantly reduced the inhibitory effect of 
bis(propyl)-cognitin, with the IC50 value increased from 0.97 ± 0.13 
μm to 45.51 ± 4.32 μm (n = 7, p < 0.001). 
Bis(propyl)-cognitin Is Increasingly Effective in 
Protecting against Escalating Levels of Glutamate-
induced Excitotoxicity  
We have previously reported that bis(heptyl)-cognitin prevents 
glutamate-induced neuronal apoptosis in CGNs (24). In the current 
study, the model of glutamate-induced excitotoxicity in CGNs was used 
to investigate further the neuroprotective activities of bis(propyl)-
cognitin in vitro. Up to 30 μm, bis(propyl)-cognitin showed no 
noticeable toxic effect on CGNs when applied alone (data not shown). 
When CGNs were pretreated with bis(propyl)-cognitin at 
concentrations from 0.1 to 30 μm for 2 h and exposed to 75 μm 
glutamate for 24 h, it was found that bis(propyl)-cognitin prevented 
glutamate-induced neuronal cell death in a concentration-dependent 
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manner with an EC50 value of 1.33 ± 0.03 μm. The neuroprotection of 
bis(propyl)-cognitin was more substantial than that of the same 
concentration of memantine (Fig. 6A). Furthermore, it has been shown 
in our previous study that the effectiveness of the neuroprotection of 
bis(heptyl)-cognitin decreases with the increase of glutamate 
concentrations, and it can hardly protect against 300–500 μm 
glutamate-induced excitotoxicity (24). Very interestingly, however, the 
neuroprotective activity of bis(propyl)-cognitin, in contrast to 
bis(heptyl)-cognitin, increased with the escalation of glutamate 
concentrations when CGNs were pretreated with 3 μm bis(propyl)-
cognitin and then exposed to glutamate (from 25 up to 500 μm) (Fig. 
6B). 
Bis(propyl)-cognitin Rescues MCAO-induced 
Impairments Much More Potently than Memantine  
The excitotoxicity associated with the NMDA receptor 
overactivation is closely involved in the pathogenesis of stroke (15, 
30). A transient focal ischemic stroke model of MCAO-induced 
impairments in rats was employed to determine the neuroprotective 
effect of bis(propyl)-cognitin in vivo. Adult male Sprague-Dawley rats 
were subjected to transient MCAO for 2 h by the intraluminal suture 
method, and intraperitoneal injection of saline or bis(propyl)-cognitin 
(0.19 and 0.65 μmol/kg) was performed 15 min after MCAO onset. As 
depicted in Fig. 7, the treatment with bis(propyl)-cognitin produced a 
dose-dependent improvement in 24-h neurological deficits with 
neurological scores reduced from 2.2 ± 0.60 (saline group) to 1.6 ± 
0.24 and 0.5 ± 0.29 for 0.19 and 0.65 μmol/kg bis(propyl)-cognitin-
treated groups, respectively. Moreover, at 0.19 and 0.65 μmol/kg, 
bis(propyl)-cognitin reduced the total infarct volume significantly from 
a vehicle control of 34.92 ± 3.79% to 29.43 ± 5.33 and 11.24 ± 
1.95% (n = 8–11 in each group, p < 0.01), respectively. Consistent 
with the previous study (31), memantine at a dose of 93 μmol/kg 
reduced the total infarct volume to 23.97%. 
Bis(propyl)-cognitin Enhances LTP Induction  
Based on the UFO characteristics of bis(propyl)-cognitin in 
antagonizing NMDA receptors, we wanted to investigate the effect of 
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bis(propyl)-cognitin on NMDA receptor-mediated physiological function 
in terms of LTP. In rat hippocampal slices, HFS induced NMDA 
receptor-dependent LTP under control conditions that reached a peak 
immediately following HFS and then slowly declined over the next 1 h 
to 45–80% above base line, and the averaged LTP was measured to 
be 149 ± 3% at 60 min post-HFS (n = 6) (Fig. 8A). We next tested 
the effect of bis(propyl)-cognitin on LTP induction. Bis(propyl)-cognitin 
at a concentration of 1 μm did not change the base line but enhanced 
LTP significantly compared with the LTP control (n = 5, p < 0.01) (Fig. 
8), and the LTP was 172 ± 4% at 60 min post-HFS. Interestingly, 
bis(propyl)-cognitin significantly increased LTP even at 10 μm, 
although the effect was lower than that at 1 μm. To compare the effect 
of different NMDA receptor antagonists, memantine and MK-801 were 
also investigated. It was found that memantine at 3 μm did not alter 
LTP induction. However, MK-801 at 1 μm was able to significantly 
inhibit LTP induction (Fig. 8B). 
Discussion 
Excitotoxicity mediated by NMDA receptors has been thought to 
be the final common pathway in a variety of neurological diseases. 
NMDA receptor antagonists with the UFO properties and moderate 
affinity are proposed to be effective and well tolerated in treating these 
diseases (3, 11). In the current study, compared with memantine and 
other dimeric AChE inhibitors derived from tacrine, the characteristics 
of bis(propyl)-cognitin to inhibit NMDA receptors and its 
neuroprotection in vitro and in vivo were investigated. We mainly 
report three novel points; bis(propyl)-cognitin 1) is an uncompetitive 
NMDA receptor antagonist with fast off-rate and moderate affinity, 2) 
possesses superior neuroprotective activities against glutamate-
induced excitotoxicity in vitro and MCAO-induced impairments in vivo, 
indicating that this dimer may prevent glutamate-induced pathological 
processes, and 3) enhances the LTP induction in hippocampal slices, 
suggesting that this dimer may not interfere with but even promote 
the NMDA receptor-mediated physiological functions. 
Bis(propyl)-cognitin is an uncompetitive NMDA receptor 
antagonist. We have reported that bis(heptyl)-cognitin, a dimeric AChE 
inhibitor, is an antagonist of NMDA receptors (24). We speculate that 
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other dimers from this series might also block NMDA receptors. 
Indeed, bis(n)-cognitins can selectively inhibit NMDA-activated 
currents with different extents of potency and voltage dependence. We 
wonder whether some of these dimers are NMDA receptor antagonists 
with the UFO properties. In comparing actions of the series of dimers 
on NMDA receptors, we single out bis(propyl)-cognitin as a promising 
UFO agent with moderate affinity based on moderate potency and 
strong voltage dependence. Uncompetitivity is the major determinant 
of safety and tolerability for NMDA receptor antagonists in clinical trials 
(11, 16). To test whether bis(propyl)-cognitin inhibition is competitive, 
non-competitive, or uncompetitive as defined by Lipton (11), we have 
examined the effect of increasing NMDA concentrations on bis(propyl)-
cognitin inhibition. The concentration-response curve for NMDA-
activated currents in the presence of bis(propyl)-cognitin is shifted 
downward. This means that an increase of NMDA concentration cannot 
overcome the inhibition of bis(propyl)-cognitin, suggesting that 
bis(propyl)-cognitin inhibition is not via a competitive mechanism. A 
further analysis of the agonist concentration dependence of 
bis(propyl)-cognitin inhibition by plotting the percentage inhibition 
against NMDA concentrations reveals that the inhibition increases with 
the increase of NMDA concentration, which is characteristic of an 
uncompetitive mechanism (10, 31). Different from memantine, which 
has been demonstrated to act on the NMDA receptor with a quite slow 
onset (32), bis(propyl)-cognitin inhibition exhibits fast onset and 
reaches equilibrium during its application (several seconds). This can 
exclude the possibility that the observed uncompetitive mechanism is 
an artifact caused by an inadequate time of drug application. 
Bis(propyl)-cognitin inhibits NMDA receptors in an agonist-
dependent manner. Because the inhibitory effect of uncompetitive 
antagonists is contingent upon prior activation of the receptor channel 
by the agonist (11), we have checked the agonist dependence of 
bis(propyl)-cognitin. We observe that bis(propyl)-cognitin co-applied 
or applied after the activation of NMDA receptors but not preapplied 
shows an inhibitory effect on NMDA-activated currents. This 
observation indicates that bis(propyl)-cognitin association with its 
acting site on the receptor requires the channel to be open, which is 
similar to the mechanism of action of memantine and MK-801, two 
NMDA receptor uncompetitive antagonists (31, 33). These 
observations strongly support the uncompetitive mechanism of action, 
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which is further supported by the use dependence of action. Use-
dependent compounds can only access their site(s) of action when the 
receptor/channel is in an activated state, resulting in a delay between 
receptor activation and the antagonist-induced blockade. Therefore, 
they are less likely to block short periods of activation, which typify 
physiological activity of NMDA receptors (34). 
Bis(propyl)-cognitin inhibition has the fast off-rate property. 
Effective and safe NMDA receptor antagonists for the treatment of 
neurodegenerative disorders are required to leave the channel quickly 
when the membrane is depolarized under physiological conditions. To 
meet this criterion, the antagonist is expected to inhibit the receptor 
channel at negative membrane potentials and can leave the channel 
quickly and have no effect at depolarized membrane potentials (e.g. 
>−20 mV) (35). The observed strong voltage dependence of 
bis(propyl)-cognitin inhibition of NMDA-activated currents may meet 
this requirement, and more importantly, the inhibition exhibits a fast 
off-rate (τoff ∼2 s), which is much faster than that of MK-801 (τoff ∼90 
min) (33). This mechanism of action enables the quick elimination of 
bis(propyl)-cognitin upon its removal or membrane depolarization, 
suggesting that this compound should be safer than MK-801 (16). The 
fast off-rate of bis(propyl)-cognitin also reflects its low affinity toward 
NMDA receptors. Like memantine (16, 26), the onset time constants 
are well correlated with bis(propyl)-cognitin concentrations, whereas 
the offset time constants are independent of its concentrations. The 
fast onset (millisecond to second time scale) of inhibition can also 
exclude second messenger-mediated mechanism because the G-
protein-coupled cascade requires several tens of seconds for the 
process of signal transduction (36), supporting the idea that 
bis(propyl)-cognitin inhibits NMDA receptors directly. 
Bis(propyl)-cognitin moderately blocks NMDA receptors at the 
MK-801 site. To further characterize acting site(s) of bis(propyl)-
cognitin, we have applied molecular docking analysis to examine the 
interaction between bis(propyl)-cognitin and NMDA receptors. 
Bis(propyl)-cognitin exhibits favorable interaction with the channel 
pore of the NMDA receptor at a similar binding score of memantine. 
The interaction of bis(propyl)-cognitin with the channel pore region is 
further proved by the fact that it moderately competes with [3H]MK-
801 binding to NMDA receptors. These results demonstrate that the 
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acting site of bis(propyl)-cognitin may overlap with that of MK-801 in 
the channel pore of the NMDA receptor. Previous study has shown that 
mutation of NR1(N616R) significantly reduced the inhibitory potency of 
Mg2+, memantine, and MK-801 (29). By using HEK293T cells 
transfected with NR1(N616R)/NR2A, it is also demonstrated that the 
inhibitory potency of bis(propyl)-cognitin is reduced. We speculate that 
the mutation interferes with the binding of bis(propyl)-cognitin to the 
region of MK-801 binding on NMDA receptors. The interaction between 
bis(propyl)-cognitin and the NMDA receptors further supports the idea 
that the inhibition is exerted by directly modulating NMDA receptors 
rather than via a second messenger-mediated mechanism. Together, 
these results suggest that bis(propyl)-cognitin is an NMDA receptor 
antagonist at the MK-801 site with moderate affinity. Increasing 
evidence has shown that the drugs with fast kinetics in moderately 
inhibiting the targeted receptors and/or enzymes may have higher 
therapeutic significance and hardly interfere with the physiological 
function of the brain (35, 37, 38). 
The UFO properties and moderate affinity are expected to 
endow bis(propyl)-cognitin with increasing protective effectiveness 
against escalating concentrations of glutamate-induced excitotoxicity 
and enable its quick relief upon depolarization associated with 
physiological neurotransmission without observable toxicity. Indeed, 
we have found that, similar to memantine but in contrast to 
bis(heptyl)-cognitin (24), bis(propyl)-cognitin is increasingly effective 
in protecting against escalating levels of glutamate-induced 
excitotoxicity without obvious cytotoxicity. Interestingly, a low 
micromolar concentration of bis(propyl)-cognitin shows more 
pronounced improvement in neurological scores and reduction in 
infarct volume in rats subjected to MCAO than does memantine (31), 
implying that bis(propyl)-cognitin may possess other relevant targets 
in vivo. Our preliminary data show that this dimer does possess 
selective inhibition on neuronal and inducible nitric-oxide synthase 
instead of endothelial nitric-oxide synthase and inhibition of voltage-
gated calcium channels.4 
We examined whether bis(propyl)-cognitin interferes with NMDA 
receptor-mediated physiological functions by investigating its effect on 
LTP induction in hippocampal slices. Similar to the previous report 
(39), MK-801 significantly reduces LTP induction, whereas memantine 
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at a relatively low concentration has no significant effect on LTP 
induction, and the differential effects of MK-801 and memantine on 
NMDA receptor-dependent LTP have been attributed to their different 
affinities and voltage dependences to antagonize NMDA receptors. 
Under the conditions of a resting membrane potential of around −70 
mV, the ion channel of the NMDA receptor is blocked by Mg2+ ions. 
Even if glutamate and glycine bind to the NMDA receptor, the Mg2+ ion 
block prevents the flow of ions (35). The Mg2+ block can be removed 
by depolarization of the cell membrane. In other words, the NMDA 
receptor only allows Ca2+ ions entering the cell if two conditions are 
fulfilled; the receptor must be activated by ligands, and the neuron 
must be depolarized (e.g. by the activation of non-NMDA receptors). 
An important aspect is that the Mg2+ block is reduced, even after slight 
depolarization of the cell membrane to around −50 mV. With the 
disruption of energy metabolism in neurodegenerative disorders, 
glutamate is not cleared properly and may even be inappropriately 
released; moreover, energetically compromised neurons become 
depolarized (more positively charged) because in the absence of 
energy the neurons cannot maintain their ionic homeostasis. This 
depolarization (around −50 mV) relieves the normal Mg2+ block of 
NMDA receptor-coupled channels because the relatively positive 
charge in the cell repels positively charged Mg2+ from the channel 
pore, and then excessive stimulation of NMDA receptors occurs. 
Recent studies suggest that NMDA receptors are overstimulated in a 
tonic rather than a phasic manner in several neurodegenerative 
disorders. Memantine is an uncompetitive and moderate antagonist of 
NMDA receptor with an appropriate voltage-dependent inhibition 
between that of Mg2+ and MK-801. This property may help memantine 
to inhibit the activation of NMDA receptors caused by a tonic and low 
concentration (50–100 μm) glutamate under relatively low depolarized 
conditions (about −50 mV; i.e. the aforementioned pathological 
conditions), which is closely involved in neuronal damage and deficits 
in synaptic plasticity, but not to interfere with the activation of NMDA 
receptors caused by a phasic and high concentration (10 mm) 
glutamate under high depolarized conditions (about −20 mV), which is 
closely involved in physiological functions of glutamate and LTP 
formation in synaptic plasticity (17, 35). As expected, bis(propyl)-
cognitin should not inhibit LTP induction because bis(propyl)-cognitin 
has a profile similar to that of memantine for inhibition of NMDA 
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receptors. However, to our surprise, bis(propyl)-cognitin is observed to 
significantly enhance the LTP induction at 1 μm and without inhibition 
even at 10 μm. This may be attributed to the increase of acetylcholine 
levels caused by AChE inhibition by bis(propyl)-cognitin because 
previous studies have reported that the hippocampus synaptic 
transmission is enhanced by the activation of α7 nACh receptors linked 
with a rise in intracellular calcium and transmitter release (40, 41). On 
the other hand, bis(propyl)-cognitin has also been reported to inhibit 
GABAA receptors (20), which may additionally contribute to the 
facilitation of LTP (21,–23). LTP is widely considered to be one of the 
major cellular mechanisms underlying learning and memory. The 
enhancement of LTP by bis(propyl)-cognitin suggests that this dimer 
might provide substantial therapeutic potentials for cognitive 
impairments associated with neurodegenerative disorders. 
Increasing evidence has shown that multifactorial 
etiopathogenesis is clearly indicated in neurodegenerative disorders, 
and multiple-drug therapy is required to address the varied 
pathological aspects of these diseases (42). Current approaches with 
one drug-one target only offer limited and transient benefits to 
patients and do not significantly delay the course of neurodegeneration 
(43). Multifunctional compounds might provide greater therapeutic 
efficacy by targeting different sites in the brain concurrently (43, 44). 
Therefore, new one drug-multiple target approaches have been 
developed expressly to target multiple sites in the central nervous 
system with single molecular entities for the treatment of these 
diseases (42). Combining these novel findings with our previous 
results (19, 20), we conjecture that over the same concentration 
range (low to submicromolar range), bis(propyl)-cognitin concurrently 
possesses anti-NMDA receptors, anti-GABAA receptors, and anti-AChE 
activities. The synergism may provide bis(propyl)-cognitin as a 
promising PAT drug candidate for effective prevention and treatment 
and even modification of the pathological processes of 
neurodegenerative disorders as well as the alleviation of the cognitive 
impairments with fewer side effects. 
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FIGURE 1.  
Tether length differential potency and voltage dependence of bis(n)-
cognitins. A, the graph shows the inhibitory effects of memantine, tacrine, 
and bis(n)-cognitins (B2C, B3C, B5C, B7C, and B10C) on 30 μm NMDA-
activated currents at a holding potential of −50 mV in cultured rat 
hippocampal neurons. Each point represents the mean of percentage 
inhibition from 5–7 neurons. The IC50 values are indicated in the graph. Inset, 
molecular structure of bis(propyl)-cognitin. B, voltage dependence of tacrine 
and bis(n)-cognitin blockade of NMDA-activated currents is analyzed by 
plotting the mean of percentage inhibition against holding potentials.  
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FIGURE 2.  
Selective, agonist- and use-dependent effects of bis(propyl)-cognitin 
inhibition. A, current traces show the effect of 10 μm bis(propyl)-cognitin 
(B3C) on 30 μm AMPA- or kainic acid (KA)-activated currents. Each row of 
traces is recorded from the same neuron and repeated in five different 
neurons. Bis(propyl)-cognitin is co-applied with AMPA or kainic acid for the 
time course indicated above each trace. B, representative current traces 
recorded from the same neuron show three different modes of drug 
application: co-application of bis(propyl)-cognitin (0.3 μm) and NMDA (30 
μm), co-application made after the onset of the response to NMDA, and 
sequential application of NMDA following bis(propyl)-cognitin preapplication. 
Note the different effects of bis(propyl)-cognitin under these different 
conditions. A similar result was obtained in four different neurons. C, 
representative current traces (top) and graph (bottom, n = 8) show the 
control NMDA response and the cumulative inhibition incurred by consecutive 
co-application of NMDA and 1 μm bis(propyl)-cognitin, followed by the 
response to NMDA alone for recovery. Each response, normalized to the first 
NMDA-activated current, is activated at intervals of 1 min. The solid bars 
indicate the application of NMDA and/or bis(propyl)-cognitin.  
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FIGURE 3.  
Bis(propyl)-cognitin is an uncompetitive inhibitor of NMDA receptors. 
A, NMDA dose-response curves in the absence (○) and presence (●) of 0.3 μm 
bis(propyl)-cognitin (B3C). The steady state response for each concentration 
of NMDA in the absence or presence of bis(propyl)-cognitin is normalized to 
the response produced by 30 μm NMDA in the absence of bis(propyl)-cognitin 
(marked with an asterisk). The responses are the means ± S.E. (error bars) 
from 9–15 neurons at each concentration of NMDA. Inset, plot showing the 
percentage inhibition of B3C and D(-)-2-amino-5-phosphonopentanoic acid 
(AP5) against NMDA concentrations ranging from 3 to 300 μm. B, dose-
response relationships for bis(propyl)-cognitin inhibition of INMDA obtained 
under the conditions of 0.1 μm (●) and 10 μm (■) glycine. The curves were 
fitted using the logistic equation under “Experimental Procedures.”  
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FIGURE 4.  
Onset and offset time constants of bis(propyl)-cognitin inhibition. A, 
traces show currents activated by 30 μm NMDA and its inhibition by 1 μm 
bis(propyl)-cognitin applied after the activation of NMDA receptors. The 
periods of drug application are indicated by the solid bar above the trace. 
White dotted lines drawn through the current trace (black part) are the 
theoretical fit of onset (τon) and offset (τoff) of bis(propyl)-cognitin inhibition 
using single exponential functions. B, graph plotting average τon (■) and τoff 
(●) values against bis(propyl)-cognitin concentration shows the concentration 
dependence of onset and offset kinetics. Error bars, S.E.  
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FIGURE 5.  
Acting site of bis(propyl)-cognitin on the NMDA receptor. A, a close-up 
view of the low energy pose of bis(propyl)-cognitin in the NMDA receptor 
channel pore generated by molecular docking. The NMDA receptor is depicted 
in ribbon form, bis(propyl)-cognitin (tan) is depicted as a stick model, and the 
surface of the ligand pocket is shown as transparent gray skin. The homology 
model of the ion channel of NMDA receptor is constructed based on the x-ray 
crystal structure of the potassium channel KcsA (Protein Data Bank code 
1BL8). B, graph shows the inhibition of [3H]MK-801 binding to rat in rat 
cerebellar cortex membrane preparations by bis(propyl)-cognitin (B3C). 
Membranes from rat cerebellar cortex were incubated with [3H]MK-801 (4 
nm) and bis(propyl)-cognitin at gradually increasing concentrations. The data, 
expressed as percentage of control, are means according to three 
independent experiments. The Ki value was calculated from the corresponding 
IC50 Value according to the equation, Ki = IC50/(1 + C/Kd), where C is the 
concentration of radioligand and Kd is the dissociation constant obtained from 
the saturation experiment (12 nm). C, representative current traces and plots 
show the concentration-response relationships for bis(propyl)-cognitin 
inhibition of currents mediated by recombinant NR1/NR2A (wild type (WT)) 
and NR1(N616R)/NR2A receptors expressed in HEK293T cells. Error bars, S.E.  
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FIGURE 6.  
Neuroprotection of bis(propyl)-cognitin in vitro. A, CGNs, at 8 days in 
vitro, were preincubated with bis(propyl)-cognitin (B3C) at different 
concentrations as indicated for 2 h and then exposed to 75 μm glutamate for 
another 24 h. Cell viability is measured using an MTT assay. All of the data, 
expressed as percentage of untreated control, are the means ± S.E. (error 
bars) of three separate experiments. Inset, plots show dose-response 
relationships for bis(propyl)-cognitin and memantine protection. B, CGNs, at 8 
days in vitro, were preincubated with 3 μm bis(propyl)-cognitin (B3C) or 
bis(heptyl)-cognitin (B7C) for 2 h and then exposed to different 
concentrations of glutamate as indicated for another 24 h. The cell survival 
after the treatment with glutamate or glutamate following bis(propyl)-cognitin 
or bis(heptyl)-cognitin preincubation is expressed as percentage of untreated 
control.  
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FIGURE 7.  
Neuroprotective activity of bis(propyl)-cognitin in vivo. A, 
representative 2,3,5-triphenyltetrazolium chloride-stained coronal brain 
sections from animals of the sham group (left column), vehicle-treated control 
group (middle column), and bis(propyl)-cognitin (B3C) (0.65 μmol/kg)-
treated group (right column), respectively. The white area represents the 
area of infarction in the brains of stroke rats. Drug or saline was 
intraperitoneally administered 15 min after the onset of MCAO, and rats were 
decapitated 24 h later. B, infarct volume for seven sequential coronal sections 
from anterior to posterior in rats receiving saline (Control) or bis(propyl)-
cognitin (0.65 μmol/kg) 15 min after the induction of ischemia. C, total infarct 
volume (left) and neurological deficit scores (right) at 24 h after reperfusion 
for saline-, bis(propyl)-cognitin (0.19 and 0.65 μmol/kg)-, and memantine 
(93 μmol/kg)-treated rats, respectively. *, p < 0.05; **, p < 0.01 compared 
with control. Error bars, S.E.  
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FIGURE 8.  
Bis(propyl)-cognitin enhances LTP. A, the graph shows induction of LTP in 
control (●) and in the presence of bis(propyl)-cognitin (B3C), perfused for 60 
min prior to HFS (○). B, statistical analyses of the effect of bis(propyl)-
cognitin, memantine, and MK-801 on LTP. The agents were perfused over the 
slices for 60 min prior to HFS, and LTP induction was recorded. All data are 
the means ± S.E. of EPSPs at 60 min after HFS (n = 5). *, p < 0.05; **, p < 
0.01 versus LTP control.  
 
 
 
